Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Platycladus orientalis leaf extract helps hair grow by activating certain proteins.

Leptin-deficient mice, used as a model for Type 2 Diabetes, have delayed wound healing due to impaired contraction and other dysfunctional cellular responses.

In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

A personalized nutrition plan improved hair and skin health in a young man.

Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.

The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Stress affects skin health, and mental health support is crucial for patients with skin conditions.

Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.

Alopecia areata is decreasing globally, affects more females, and is linked to anxiety and atopic dermatitis, especially in children.

Oral minoxidil may have more cardiovascular risks than topical minoxidil.

JAK1 gene variation may increase alopecia areata risk.

The conference highlighted new treatments and research in pediatric skin conditions, emphasizing collaboration and innovation.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Epidermal signaling helps regenerate fingertip tissue.

High levels of ERK activity are key for tissue regeneration in spiny mice, and activating ERK can potentially redirect scar-forming healing towards regenerative healing in mammals.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Tissue stiffness affects hair follicle regeneration, and Twist1 is a key regulator.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.